We found that copy number amp/gain of NSD1 or PRDM1, or loss of SETDB2 or PRDM10 was significantly associated (p<0.05) with shorter survival in breast cancer patients (Supplementary Table S7). Here, PRDM10 is linked to breast carcinoma.